Vertex and CRISPR Therapeutics to use gene editing technology to develop new treatments for genetic diseases

Published: 26-Oct-2015
Research & Development

Vertex will take a US$30m stake in CRISPR and make an upfront payment of $75m


Boston, MA-based cystic fibrosis drugmaker Vertex Pharmaceuticals is committing US$105m in cash to embrace CRISPR Therapeutics' gene editing technology to discover and develop potential new treatments aimed at the genetic causes of human disease.

Vertex will pay $75m to CRISPR in cash in an upfront payment while taking a $30m equity stake in the company in exchange for the right to license up to six gene-editing treatments that could result from a research partnership between the two firms.

CRISPR could also receive future development, regulatory and sales milestones and royalty payments of up to $420m on future sales.

The four-year research collaboration will evaluate the use of CRISPR-Cas9 technology across multiple diseases where targets have been validated through human genetics.

For CRISPR, this collaboration validates the potential for gene editing in human therapeutics

Vertex and CRISPR will focus their initial gene editing research on discovering treatments to address the mutations and genes known to cause and contribute to cystic fibrosis and sickle cell disease. They will also evaluate a specified number of other genetic targets as part of the collaboration.

'CRISPR-Cas9 is an important scientific and technological breakthrough that holds significant promise for the future discovery of potentially transformative treatments for many genetic diseases,' said David Altshuler, Vertex's Executive Vice President, Global Research and Chief Scientific Officer.

Rodger Novak, Chief Executive of CRISPR Therapeutics, added: 'Vertex has a track record of developing innovative medicines for cystic fibrosis and other serious diseases, making them a great partner to accelerate the therapeutic promise of gene editing.

'For CRISPR, this collaboration validates the potential for gene editing in human therapeutics and provides important financial support for continued investment in our platform and proprietary pipeline of programmes.'

  • Companies:
  • Vertex Pharmaceuticals
  • CRISPR Therapeutics
See more

You may also like

Research & Development

CRISPR Therapeutics and MaSTherCell SA develop allogeneic cell therapies

Read more
CRISPR Therapeutics and MaSTherCell SA sign an agreement to develop and manufacture allogeneic CAR-T therapies

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Thermo Fisher Scientific officially opens US oral solid dose testing and R&D facility The company's further expansion in the Bend, Oregon area will assist its pharmaceutical clients in the early development of oral solid dosage (OSD) forms
  3. BioMarin Pharmaceutical expands Cork targeted therapy manufacturing facility with new lab The Irish facility is responsible for the development and commercialisation of therapies that address genetic conditions, and this expansion will allow the company to enhance its approved medicine production capacity
  4. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

CRISPR Therapeutics and MaSTherCell SA develop allogeneic cell therapies

CRISPR Therapeutics and MaSTherCell SA sign an agreement to develop and manufacture allogeneic CAR-T therapies
Research & Development

Casebia Therapeutics establishes operations in Cambridge (MA, USA)

Hiring is underway and efforts have begun on haematology and ophthalmology programmes
Research & Development

Vertex and Moderna collaborate to develop mRNA Therapeutics for cystic fibrosis

Moderna will receive $40 million upfront, with potential for an additional $275m in milestones and royalty payments
Research & Development

Pipeline advancements and asset acquisitions fuelled mid-cap biotech R&D spend in 2014

Combined R&D spend of 35 mid-cap biotech companies increased by nearly US$2bn to reach a total of $9.7bn in 2014
Media

Orphan drugs market offers many opportunities for drug development, says new study

Breakthrough therapies for rare diseases command premium prices, particularly if no alternatives exist
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Drug approvals: more numerous but niche

After many years of low approval rates, in 2012 more than 30 new drugs were approved by the European Medicines Agency. Although many of them were niche products, some were for diseases with large patient populations, such as diabetes and various forms of cancer
Regulatory

Cystic fibrosis – ivacaftor

Since the discovery of the gene responsible for cystic fibrosis, CFTR or cystic fibrosis transmembrane regulator gene, several mutations have been found that lead to the production of abnormal CFTR protein
Subscribe now